The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > ORGANIZATION
ORGANIZATION
- Nichi-Iko Suspended from JGA Membership
March 10, 2021
- Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
March 5, 2021
- Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
February 22, 2021
- 76% Sees Healthcare as Top Priority in COVID-19 Response: PhRMA Japan Survey
February 19, 2021
- PhRMA Japan Chief Urges Govt to Return to Pro-Innovation Path, Airs Grievances over Decision-Making on Off-Year Price Cuts
February 19, 2021
- Kobayashi Kako Expelled from JGA over Drug Mix-Up
February 10, 2021
- PhRMA Prods Japan to Harness Power of RWD in Drug Development, Medical Care Evaluation
February 3, 2021
- JPMA, National Centers to Build Integrated Database for Drug Discovery; 1st Focus on Neurology/Psychiatry, Immune/Inflammation
January 26, 2021
- 3 Indicted Wholesalers Barred from JCHO/NHO Bids, but Can Sell Single-Channel Drugs to Ensure Access
January 26, 2021
- JPMA Exec Raps Off-Year Re-Pricing Plan, Says It Significantly Mars Predictability
January 22, 2021
- Generic Use Targets Should Be Set by City/Ward in Major Prefectures: Professor
January 14, 2021
- Yaz Generics to Carry Single Brand Name of DroEthi
January 13, 2021
- JPMA Chief Vows Renewed Efforts to Deliver COVID-19 Drugs, Vaccines as Japan Declares 2nd Emergency
January 12, 2021
- Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
- 5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing
January 5, 2021
- First Time FPMAJ’s Supply Coordination Scheme Invoked for 13 APIs Tied to Kobayashi Kako
January 5, 2021
- Corporate Culture, Attitude of Management at Root of Kobayashi Kako Scandal: MHLW Official
January 5, 2021
- Tohoku Univ, JPMA, MICIN Launch Pilot Study on Wearable Data Collection
December 24, 2020
- National Hospital Organization to Switch from Kobayashi Kako Products after Itraconazole Mix-Up
December 22, 2020
- 3 Hospitals in Wakayama to Select Recommended Drugs after Mass Generic Recalls, De-Facto Regional Formulary
December 22, 2020
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…